Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Corrigendum: Muramyl Endopeptidase Spr Contributes to Intrinsic Vancomycin Resistance in Salmonella enterica Serovar Typhimurium.

Vestö K, Huseby DL, Snygg I, Wang H, Hughes D, Rhen M.

Front Microbiol. 2019 Mar 5;10:386. doi: 10.3389/fmicb.2019.00386. eCollection 2019.

2.

In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii.

Juhas M, Widlake E, Teo J, Huseby DL, Tyrrell JM, Polikanov YS, Ercan O, Petersson A, Cao S, Aboklaish AF, Rominski A, Crich D, Böttger EC, Walsh TR, Hughes D, Hobbie SN.

J Antimicrob Chemother. 2019 Apr 1;74(4):944-952. doi: 10.1093/jac/dky546.

3.

Muramyl Endopeptidase Spr Contributes to Intrinsic Vancomycin Resistance in Salmonella enterica Serovar Typhimurium.

Vestö K, Huseby DL, Snygg I, Wang H, Hughes D, Rhen M.

Front Microbiol. 2018 Dec 14;9:2941. doi: 10.3389/fmicb.2018.02941. eCollection 2018. Erratum in: Front Microbiol. 2019 Mar 05;10:386.

4.

Effect of aminoacyl-tRNA synthetase mutations on susceptibility to ciprofloxacin in Escherichia coli.

Garoff L, Huseby DL, Praski Alzrigat L, Hughes D.

J Antimicrob Chemother. 2018 Dec 1;73(12):3285-3292. doi: 10.1093/jac/dky356.

PMID:
30239743
5.

Odilorhabdins, Antibacterial Agents that Cause Miscoding by Binding at a New Ribosomal Site.

Pantel L, Florin T, Dobosz-Bartoszek M, Racine E, Sarciaux M, Serri M, Houard J, Campagne JM, de Figueiredo RM, Midrier C, Gaudriault S, Givaudan A, Lanois A, Forst S, Aumelas A, Cotteaux-Lautard C, Bolla JM, Vingsbo Lundberg C, Huseby DL, Hughes D, Villain-Guillot P, Mankin AS, Polikanov YS, Gualtieri M.

Mol Cell. 2018 Apr 5;70(1):83-94.e7. doi: 10.1016/j.molcel.2018.03.001.

6.

Imidazopyrazinones (IPYs): Non-Quinolone Bacterial Topoisomerase Inhibitors Showing Partial Cross-Resistance with Quinolones.

Jeannot F, Taillier T, Despeyroux P, Renard S, Rey A, Mourez M, Poeverlein C, Khichane I, Perrin MA, Versluys S, Stavenger RA, Huang J, Germe T, Maxwell A, Cao S, Huseby DL, Hughes D, Bacqué E.

J Med Chem. 2018 Apr 26;61(8):3565-3581. doi: 10.1021/acs.jmedchem.7b01892. Epub 2018 Apr 10.

PMID:
29596745
7.

Methods to Determine Mutational Trajectories After Experimental Evolution of Antibiotic Resistance.

Huseby DL, Hughes D.

Methods Mol Biol. 2018;1736:95-103. doi: 10.1007/978-1-4939-7638-6_9.

PMID:
29322462
8.

Early-Life Human Microbiota Associated With Childhood Allergy Promotes the T Helper 17 Axis in Mice.

Petursdottir DH, Nordlander S, Qazi KR, Carvalho-Queiroz C, Ahmed Osman O, Hell E, Björkander S, Haileselassie Y, Navis M, Kokkinou E, Lio IZL, Hennemann J, Brodin B, Huseby DL, Nilsson C, Hughes D, Udekwu KI, Sverremark-Ekström E.

Front Immunol. 2017 Dec 1;8:1699. doi: 10.3389/fimmu.2017.01699. eCollection 2017.

9.

Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli.

Praski Alzrigat L, Huseby DL, Brandis G, Hughes D.

J Antimicrob Chemother. 2017 Nov 1;72(11):3016-3024. doi: 10.1093/jac/dkx270.

10.
11.

Alternative Evolutionary Pathways for Drug-Resistant Small Colony Variant Mutants in Staphylococcus aureus.

Cao S, Huseby DL, Brandis G, Hughes D.

MBio. 2017 Jun 20;8(3). pii: e00358-17. doi: 10.1128/mBio.00358-17.

12.

Mutation Supply and Relative Fitness Shape the Genotypes of Ciprofloxacin-Resistant Escherichia coli.

Huseby DL, Pietsch F, Brandis G, Garoff L, Tegehall A, Hughes D.

Mol Biol Evol. 2017 May 1;34(5):1029-1039. doi: 10.1093/molbev/msx052.

13.

Design, synthesis and in vitro biological evaluation of oligopeptides targeting E. coli type I signal peptidase (LepB).

De Rosa M, Lu L, Zamaratski E, Szałaj N, Cao S, Wadensten H, Lenhammar L, Gising J, Roos AK, Huseby DL, Larsson R, Andrén PE, Hughes D, Brandt P, Mowbray SL, Karlén A.

Bioorg Med Chem. 2017 Feb 1;25(3):897-911. doi: 10.1016/j.bmc.2016.12.003. Epub 2016 Dec 7.

14.

Ciprofloxacin selects for RNA polymerase mutations with pleiotropic antibiotic resistance effects.

Pietsch F, Bergman JM, Brandis G, Marcusson LL, Zorzet A, Huseby DL, Hughes D.

J Antimicrob Chemother. 2017 Jan;72(1):75-84. Epub 2016 Sep 12.

PMID:
27621175
15.

Evidence that a metabolic microcompartment contains and recycles private cofactor pools.

Huseby DL, Roth JR.

J Bacteriol. 2013 Jun;195(12):2864-79. doi: 10.1128/JB.02179-12. Epub 2013 Apr 12.

16.

Intestinal inflammation allows Salmonella to use ethanolamine to compete with the microbiota.

Thiennimitr P, Winter SE, Winter MG, Xavier MN, Tolstikov V, Huseby DL, Sterzenbach T, Tsolis RM, Roth JR, Bäumler AJ.

Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17480-5. doi: 10.1073/pnas.1107857108. Epub 2011 Oct 3.

17.

Gut inflammation provides a respiratory electron acceptor for Salmonella.

Winter SE, Thiennimitr P, Winter MG, Butler BP, Huseby DL, Crawford RW, Russell JM, Bevins CL, Adams LG, Tsolis RM, Roth JR, Bäumler AJ.

Nature. 2010 Sep 23;467(7314):426-9. doi: 10.1038/nature09415.

Supplemental Content

Loading ...
Support Center